Vivani Medical, Inc. (VANI)
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Biotechnology
Vivani Medical, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 90.20M shares outstanding
USVivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need.
It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
The company is headquartered in Emeryville, California.
Leadership
Aaron Mendelsohn
Director
Adam Mendelsohn
Co-Founder, Chief Executive Officer & Director
Adam Mendelsohn, Ph.D.
Chief Executive Officer and Director
Anthony Baldor
Chief Financial Officer
Employees
37
Country
US
Sector
Healthcare
Website
vivani.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Mendelsohn Aaron | Director | Withholding/Transfer | 20.0K | -- | Oct 15, 2026 |
 Porter Lisa Ellen | Chief Medical Officer | Grant/Award | 40.0K | -- | Jul 28, 2026 |
 Baldor Anthony | Chief Financial Officer | Grant/Award | 37.5K | -- | Jul 28, 2026 |
| Baldor Anthony | Chief Financial Officer | Grant/Award | 75.0K | -- | Jul 28, 2026 |
 Dwyer Donald | Chief Business Officer | Grant/Award | 70.0K | -- | Jul 28, 2026 |
| Dwyer Donald | Chief Business Officer | Grant/Award | 35.0K | -- | Jul 28, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Williams Gregg · joint filing· may incl. warrants· filed May 2026 | 43.2M | 47.9% | 13D |
VANGUARD CAPITAL MANAGEMENT LLC | 1.8M | 2.0% | 13F |
Tanager Wealth Management LLP | 607.3K | 0.7% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 587.7K | 0.7% | 13F |
TUDOR INVESTMENT CORP ET AL | 410.9K | 0.5% | 13F |
COMMONWEALTH EQUITY SERVICES, LLC | 330.6K | 0.4% | 13F |
VANGUARD FIDUCIARY TRUST CO | 325.5K | 0.4% | 13F |
BlackRock, Inc. | 301.8K | 0.3% | 13F |
MONETARY MANAGEMENT GROUP INC | 194.0K | 0.2% | 13F |
 Mendelsohn Aaron Director | 168.2K | 0.2% | FORM 4 |
Insiders
- Mendelsohn AaronDirector
- Porter Lisa EllenChief Medical Officer
- Baldor AnthonyChief Financial Officer
- Dwyer DonaldChief Business Officer
- Mendelsohn AdamChief Executive Officer
- Le TrucChief Operations Officer
- BRADBURY DANIELDirector
- Williams GreggDirector
- Popoff Alexandra L.Director
- Moretti August JDirector
based on 90.20M shares outstanding
US30d Avg
148.62K
60d Avg
197.13K
90d Avg
187.35K